A Phase 3 interventional study of Comparator: atorvastatin and Comparator: Placebo in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-05-13.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 38th largest by enrollment of the 97 interventional ones that give a count, is one of 6 that started in 2006, is one of 50 in phase 3, and was the 14th registered.
1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 6 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 196 is above the median of 109 across 978 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 50th largest by enrollment of the 81 interventional ones that give a count, is one of 7 that started in 2006, is one of 58 in phase 3, and was the 25th registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate and compare the efficacy and safety of ezetimibe plus atorvastatin versus atorvastatin in hypercholesterolemic patients at moderately high risk for coronary heart disease not adequately controlled on atorvastatin 20 mg.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Atorvastatin 40mg tablet + Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day).
Drug: Comparator: atorvastatin · Drug: Comparator: Placebo
Atorvastatin 40mg Pbo tablet + Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day).
Drug: Comparator: ezetimibe · Drug: Comparator: Placebo.
Atorvastatin 40mg tablet po qd (by mouth, once a day) for 6 weeks
Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks
Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day). for 6 weeks.
Atorvastatin 40mg Pbo tablets po qd (by mouth, once a day). for 6 weeks.
Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6
\[(6 week value - baseline value)/baseline value\]\*100%.
Time frame: 6 weeks
Percent Change in High Density Lipoprotein -Cholesterol (HDL-C)at Week 6
\[(6 week value - baseline value)/baseline value\]\*100%.
Time frame: 6 weeks
Percent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6
\[(6 week value - baseline value)/baseline value\]\*100%.
Time frame: 6 Weeks
Percent Change From Baseline in Total-Cholesterol at Week 6
(\[6 week value - baseline value)/baseline value\]\*100%.
Time frame: 6 Weeks
Percent Change From Baseline in Triglycerides (TG) at Week 6
\[(6 week value - baseline value)/baseline value\]\*100%.
Time frame: 6 weeks
Percent Change From Baseline in Apolipoprotein B at Week 6
\[(6 week value - baseline value)/baseline value\]\*100%.
Time frame: 6 Weeks
Percent Change From Baseline in Total-Cholesterol:High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
\[(6 week value - baseline value)/baseline value\]\*100%.
Time frame: 6 Weeks
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
\[(6 week value - baseline value)/baseline value\]\*100%.
Time frame: 6 Weeks
Percent Change From Baseline in Apolipoprotein B: Apolipoprotein A-I Ratio at Week 6
\[(6 week value - baseline value)/baseline value\]\*100%.
Time frame: 6 Weeks
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
\[(6 week value - baseline value)/baseline value\]\*100%.
Time frame: 6 Weeks
Percent Change From Baseline in C-Reactive Protein (CRP) at Week 6
\[(6 week value - baseline value)/baseline value\]\*100%.
Time frame: 6 Weeks
Number of Participants Who Attained Target LDL-C <100 mg/dL at Week 6
Time frame: 6 weeks
Phase III First Patient In: 4/5/2006; Last Patient Last Visit 1/17/2008 72 centers worldwide (US, Canada, Austria, Costa Rica) Eligible patients include those on a stable dose of atorvastatin 20 mg; or patients with adjusted LDL-C pre-screen ranges who were treated with other lipid modifying therapy, or were statin and/or ezetimibe naïve.
| Milestone | Atorvastatin + Ezetimibe | Atorvastatin |
|---|---|---|
| Started | 98 | 98 |
| Completed | 92 | 91 |
| Not completed | 6 | 7 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Protocol violation | 4 | 3 |
\[(6 week value - baseline value)/baseline value\]\*100%.
| Percent | Atorvastatin + Ezetimibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6 | -30.8 (-34.5 to -27.0) | -10.9 (-14.7 to -7.1) |
\[(6 week value - baseline value)/baseline value\]\*100%.
| Percent | Atorvastatin + Ezetimibe | Atorvastatin |
|---|---|---|
| Percent Change in High Density Lipoprotein -Cholesterol (HDL-C)at Week 6 | 3.2 (0.2 to 6.2) | 0.8 (-2.2 to 3.8) |
\[(6 week value - baseline value)/baseline value\]\*100%.
| Percent | Atorvastatin + Ezetimibe | Atorvastatin |
|---|---|---|
| Percent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6 | -26.7 (-30.1 to -23.3) | -10.2 (-13.6 to -6.9) |
(\[6 week value - baseline value)/baseline value\]\*100%.
| percent | Atorvastatin + Ezetimibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline in Total-Cholesterol at Week 6 | -19.7 (-22.2 to -17.1) | -7.4 (-10.0 to -4.9) |
\[(6 week value - baseline value)/baseline value\]\*100%.
| Percent | Atorvastatin + Ezetimibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline in Triglycerides (TG) at Week 6 | -17.8 (-23.7 to -11.4) | -5.5 (-14.4 to 0.0) |
\[(6 week value - baseline value)/baseline value\]\*100%.
| Percent | Atorvastatin + Ezetimibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at Week 6 | -21.4 (-24.3 to -18.5) | -7.7 (-10.6 to -4.8) |
\[(6 week value - baseline value)/baseline value\]\*100%.
| Percent | Atorvastatin + Ezetimibe | Atorvastatin |
|---|---|---|
| Percent Change in Apolipoprotein A-I at Week 6 | -1.9 (-4.2 to 0.4) | -1.2 (-3.5 to 1.1) |
\[(6 week value - baseline value)/baseline value\]\*100%.
| Percent | Atorvastatin + Ezetimibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline in Total-Cholesterol:High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6 | -20.6 (-23.7 to -17.5) | -7.5 (-10.6 to -4.4) |
\[(6 week value - baseline value)/baseline value\]\*100%.
| Percent | Atorvastatin + Ezetimibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6 | -31.9 (-35.8 to -27.9) | -11.0 (-14.9 to -7.0) |
\[(6 week value - baseline value)/baseline value\]\*100%.
| Percent | Atorvastatin + Ezetimibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B: Apolipoprotein A-I Ratio at Week 6 | -19.0 (-22.3 to -15.6) | -5.8 (-9.2 to -2.5) |
\[(6 week value - baseline value)/baseline value\]\*100%.
| Percent | Atorvastatin + Ezetimibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6 | -27.2 (-31.4 to -23.0) | -9.9 (-14.1 to -5.7) |
\[(6 week value - baseline value)/baseline value\]\*100%.
| percent | Atorvastatin + Ezetimibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline in C-Reactive Protein (CRP) at Week 6 | -6.7 (-23.7 to 14.2) | -9.2 (-25.8 to 11.1) |
\[(6 week value - baseline value)/baseline value\]\*100%.
| Percent | Atorvastatin + Ezetimibe | Atorvastatin |
|---|---|---|
| Percent Change in C-Reactive Protein (CRP) at Week 6 | -19.2 (-25.0 to -4.0) | -9.1 (-22.2 to 5.3) |
| Participants | Atorvastatin + Ezetimibe | Atorvastatin |
|---|---|---|
| <100 mg/dL | 77 | 45 |
| ≥100 mg/dL | 15 | 47 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atorvastatin + Ezetimibe | — | 0/96 (0%) | 17/96 (17.7%) |
| Atorvastatin | — | 0/98 (0%) | 22/98 (22.4%) |
| Event | Atorvastatin + Ezetimibe | Atorvastatin |
|---|---|---|
| VertigoEar and labyrinth disorders | 2/96 | 0/98 |
| FatigueGeneral disorders | 2/96 | 1/98 |
| NasopharyngitisInfections and infestations | 2/96 | 0/98 |
| Irritable bowel syndromeGastrointestinal disorders | 0/96 | 2/98 |
| Abdominal tendernessGastrointestinal disorders | 1/96 | 0/98 |
| Chest DiscomfortGeneral disorders | 1/96 | 0/98 |
| EdemaGeneral disorders | 1/96 | 0/98 |
| GastroenteritisInfections and infestations | 1/96 | 1/98 |
| Oral herpesInfections and infestations | 1/96 | 0/98 |
| Upper respiratory tract infectionInfections and infestations | 1/96 | 0/98 |
| Age, Continuous(years) | Atorvastatin + Ezetimibe | Atorvastatin | Total |
|---|---|---|---|
| Mean | 56.4 (24 to 78) | 58.0 (34 to 76) | 57.2 (24 to 78) |
| Sex: Female, Male(Participants) | Atorvastatin + Ezetimibe | Atorvastatin | Total |
|---|---|---|---|
| Female | 40 | 49 | 89 |
| Male | 58 | 49 | 107 |
| Race/Ethnicity, Customized(participants) | Atorvastatin + Ezetimibe | Atorvastatin | Total |
|---|---|---|---|
| White | 58 | 60 | 118 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 7 | 8 | 15 |
| Black | 3 | 9 | 12 |
| Multi-Racial | 29 | 21 | 50 |
| Apolipoprotein A-I(mg/dL) | Atorvastatin + Ezetimibe | Atorvastatin | Total |
|---|---|---|---|
| Mean | 161.8 ± 25.2 | 163.4 ± 24.6 | 162.6 ± 24.8 |
| Apolipoprotein A-I:Apolipoprotein B ratio(Ratio) | Atorvastatin + Ezetimibe | Atorvastatin | Total |
|---|---|---|---|
| Mean | 0.8 ± 0.2 | 0.7 ± 0.2 | 0.8 ± 0.2 |
| Apolipoprotein B(mg/dL) | Atorvastatin + Ezetimibe | Atorvastatin | Total |
|---|---|---|---|
| Mean | 122.9 ± 22.4 | 119.9 ± 21.0 | 121.4 ± 21.7 |
| C Reactive Protein(mg/dL) | Atorvastatin + Ezetimibe | Atorvastatin | Total |
|---|---|---|---|
| Mean | 1.6 ± 2.6 | 1.2 ± 1.7 | 1.5 ± 2.1 |
| High Density Lipoprotein (HDL)(mg/dL) | Atorvastatin + Ezetimibe | Atorvastatin | Total |
|---|---|---|---|
| Mean | 51.1 ± 12.1 | 51.7 ± 11.5 | 51.4 ± 11.8 |
7 further baseline measures are reported on the registry.
No study locations are listed for this record.
Plan to share: No
The record gives a start of Feb 2006, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ezetimibe